Brokerage firm Maxim Group Downgrades its rating on Inovio Pharmaceuticals Inc(NASDAQ:INO). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by Maxim Group was issued on Aug 9, 2016.
Inovio Pharmaceuticals Inc (INO) shares turned negative on Wednesdays trading session with the shares closing down -0.18 points or -2.05% at a volume of 9,18,410. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $8.831. The peak price level was also seen at $8.831 while the days lowest was $8.5285. Finally the shares closed at $8.58. The 52-week high of the shares is $11.69 while the 52-week low is $4.5. According to the latest information available, the market cap of the company is $631 M.
Inovio Pharmaceuticals Inc(INO) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $6.20M. Analysts had an estimated revenue of $4.95M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.21.
Several Insider Transactions has been reported to the SEC. On Jun 29, 2016, Morton Collins (director) purchased 10,000 shares at $9.13 per share price.Also, On May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price.On Sep 30, 2015, Niranjan Sardesai (COO) purchased 4,000 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.